Home » Newsletters » BioWorld Science

BioWorld Science

March 30, 2012

View Archived Issues

Virus-mediated neuroprotection demonstrated in model of Parkinson's disease

New protein kinase modulators designed by Ambit Biosciences

Lexicon Pharmaceuticals provides first description of early development of LX-4211

Researchers at Vertex Pharmaceuticals identify new selective PLK1 inhibitor

Gruenenthal team prepares novel voltage-gated potassium channel modulators

Merck & Co. synthesizes novel ERK inhibitors

Scientists at Merck KGaA patent new protein kinase inhibitors

Anacetrapib improves dyslipidemia in Japanese trial

Antisense therapy shows promise in phase I study

New details disclosed on phase I cenderitide trial

Abide Therapeutics and Scynexis announce collaboration

Phase I trials of e-Therapeutics anticancer drug clear to proceed

FDA clarifies dose and warning recommendations for antidepressant

SymBio's notification for phase I rigosertib study accepted in Japan

Kiklin capsules approved in Japan

U.S. university researchers prepare novel c-Met inhibitors

GSK and DSP set to copromote antidepressant in Japan

Apokyn approved for marketing in Japan

New mTOR inhibitors presented by Merck & Co.

Zeria files for approval of oral phosphate hypophosphatemia drug in Japan

Chugai obtains approval in Japan for cystic fibrosis treatment

Toray and Taiho discontinue codevelopment of beta3-adrenoceptor agonist

Pfizer and Astellas amend Lipitor licensing agreement

New product approved for T-cell leukemia-lymphoma

GenSpera advances phase I study of lead chemotherapeutic agent

Optimer and Astellas enter commercialization agreement for fidaxomicin tablets

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 12, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...